Ensysce Biosciences (ENSCW) Accounts Payables (2017 - 2025)

Ensysce Biosciences (ENSCW) has 9 years of Accounts Payables data on file, last reported at $3.3 million in Q4 2025.

• Accounts Payables for Q4 2025 came in at $3.3 million, up 140.78% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.3 million (up 140.78% YoY), and the FY2025 annual result was $3.3 million, up 140.78% from the prior year.
• Accounts Payables rose to $3.3 million in Q4 2025 per ENSCW's latest filing, from $463458.0 in the prior quarter.
• Over five years, Accounts Payables peaked at $3.3 million in Q4 2025 and troughed at $301104.0 in Q4 2021.
• A 5-year average of $1.4 million and a median of $1.2 million in 2023 frame the typical range for Accounts Payables.
• On a YoY basis, Accounts Payables climbed as much as 1818.74% in 2021 and fell as far as 90.87% in 2021.
• A 5-year view of Accounts Payables shows it stood at $301104.0 in 2021, then soared by 877.67% to $2.9 million in 2022, then slumped by 34.23% to $1.9 million in 2023, then dropped by 29.9% to $1.4 million in 2024, then soared by 140.78% to $3.3 million in 2025.
• Business Quant data shows ENSCW's Accounts Payables at $3.3 million in Q4 2025, $463458.0 in Q3 2025, and $1.0 million in Q2 2025.